How Much Weight Can You Lose Microdosing GLP-1?

The single most-searched question about microdosing GLP-1 is also the one with the weakest evidence behind any confident answer: how much weight can you actually lose? You'll see numbers thrown around — "people lose 10–15% on a fraction of the dose" — and they sound authoritative. They are not. They come from anecdote and clinic marketing, not from a trial. So this page does something the marketing won't: it puts the honest, unproven low-dose figure next to the proven full-dose trial numbers, and lets you see the gap.

The short version: the loosely reported low-dose figure clusters around roughly 12% over six months, but that comes from self-reports and clinic claims with no randomized trial behind it ¹. The full, FDA-approved doses produced about 15% with semaglutide and about 21% with tirzepatide in large randomized trials ²³. The most defensible reading is that a microdose, if it works at all, lands below the full-dose result — not equal to it.

Where the "~12%" microdose figure comes from (and why to distrust it)

Let's be precise about the provenance of the low-dose number, because that's the whole game in a YMYL topic like this.

There is no randomized controlled trial of intentional GLP-1 microdosing. None. The practice grew out of patient communities and telehealth marketing during a period of GLP-1 compounding restrictions, and the clinical literature that addresses microdosing directly does so as a caution — flagging dosing errors, unregulated sourcing, and the absence of efficacy data — not as confirmation that you'll lose a specific amount ¹. So the "~12% in six months" you'll see quoted is a synthesis of self-reported outcomes and provider claims. It is not a measured result, it has no placebo arm, and it is wide open to selection bias (people who do well are louder) and to the simple fact that low-dose users are also dieting and exercising. Treat any specific microdose weight-loss promise as a hypothesis, not a finding.

What the full doses actually produced — the real trial numbers

By contrast, here is what is known, from large randomized trials at the full approved doses.

Semaglutide (Wegovy), full 2.4 mg weekly. In STEP 1, adults with overweight or obesity lost a mean of 14.9% of body weight versus 2.4% on placebo over 68 weeks — a treatment difference of about 12.4 percentage points ². That is the headline semaglutide result, and it required the full maintenance dose reached after months of titration ⁴.

Tirzepatide (Zepbound), full doses. In SURMOUNT-1, mean weight loss at 72 weeks was 15.0% at 5 mg and 20.9% at the top 15 mg dose, versus 3.1% on placebo ³. In SURMOUNT-2, in people with type 2 diabetes, tirzepatide again produced large, dose-dependent loss ⁵. Tirzepatide's higher ceiling is why it tops most rankings.

These numbers are the benchmark a microdose is implicitly compared against — and the comparison is not flattering, because microdoses sit far below even the lowest doses used in these trials.

The dose-response reality: lower dose, less loss

The reason a microdose almost certainly underperforms isn't ideology — it's pharmacology, and there's direct data. A phase 2 dose-ranging trial gave several semaglutide doses and measured the difference: weight loss scaled cleanly with dose, from about 6% at 0.05 mg up to roughly 14% at 0.4 mg ⁶. The curve is steep at the low end — each step down costs a visible chunk of effect — and a microdose sits below even that lowest 0.05 mg arm. SURMOUNT-1's own dose spread tells the same story: 5 mg gave 15.0%, 15 mg gave 20.9% ³. More drug, more loss.

This is mechanistically expected. GLP-1 medications work by mimicking the gut hormone GLP-1 — slowing gastric emptying, suppressing glucagon, and acting on appetite centers in the brain — and those effects depend on enough drug being present to occupy enough receptors ⁷. Drop the dose far enough and you drop below the level needed to move appetite and weight meaningfully. We walk through the curve in detail in GLP-1 dose-response: why lower doses do less.

The honest math: best case, realistic case

If you want a framework rather than a promise:

• •Best case for a microdose: a modest loss, plausibly in the mid-to-high single digits if the dose is high enough to do something — roughly in line with the bottom of the dose-finding curve, where 0.05 mg gave about 6% over 68 weeks in a trial setting with structured support ⁶. The widely circulated "~12%" sits at the optimistic edge of self-report and likely reflects people who are also dieting hard.
• •Realistic case: less than the full-dose 15–21%, with a real chance of substantially less, and no guarantee of anything, because nobody has run the trial ¹.
• •What it won't reliably do: match the full-dose result. Anyone telling you a microdose delivers "most of the benefit for a fraction of the dose" is making a claim the evidence doesn't support.

Whatever you lose, sustaining it depends on staying on

One more honest caveat about how much weight: the question isn't only how much you lose, but how much you keep. In STEP 4, people who stopped semaglutide regained weight, while those who continued held their loss ⁸; the STEP 1 extension found participants regained about two-thirds of their lost weight in the year after stopping ⁹; and SURMOUNT-4 showed continued tirzepatide was needed to maintain the reduction ¹⁰. A dose too low to sustain an effect has the same regain problem as stopping entirely. We cover the keep-it-off question in using a microdose to maintain weight loss and how to taper off GLP-1 without regaining.

"Less benefit" doesn't mean "less risk," and microdosing isn't free of either

A lower dose may ease some dose-related side effects, but it doesn't make GLP-1s risk-free, and microdosing is overwhelmingly done with compounded product. A pharmacovigilance analysis of compounded GLP-1 agonists found markedly elevated reporting odds for preparation errors, contamination, and compounding problems, plus more reports of abdominal pain and hospitalization ¹¹. So the trade isn't "same benefit, less risk" — it's more honestly "less benefit, different risks." If you're choosing a pen-based approach, see our explainer on how many units is a microdose in an Ozempic or Wegovy pen?.

The bottom line

How much weight can you lose microdosing GLP-1? Honestly: unknown, probably less than the full dose, with no trial to pin a number to. The circulated "~12% in six months" is anecdote and marketing, not a measured result ¹. The proven figures — about 15% for semaglutide and about 21% for tirzepatide — came from full doses in randomized trials ²³, and the dose-response data show effects shrinking steadily as the dose falls ⁶. Expect less, demand evidence for any specific promise, and decide with a qualified clinician.

For the wider picture, start with our pillar, microdosing GLP-1: what the evidence actually shows, and the side-by-side in low-dose vs full-dose GLP-1: what actually changes. See also does microdosing GLP-1 actually work? and our deep dive on microdosing semaglutide. To compare providers, see our GLP-1 microdose rankings hub.